Posters

Effect of aflibercept induction therapy on choroidal neovascularization size using optical coherence tomography angiography

Poster Details

First Author: N.Miyamoto JAPAN

Co Author(s):    M. Mandai   S. Takagi   A. Nishida   Y. Kurimoto                    

Abstract Details



Purpose:

We reported previously that of all treatment-naïve age-related macular degeneration (AMD) patients, 80% well-responded to aflibercept induction therapy by achieving complete resolution of the fluid (2014 ARVO); however, the resultant course of changes in choroidal neovascularization (CNV) size during aflibercept induction therapy is not well known. In the present study, we evaluated the changes of CNV size in patients with AMD who received aflibercept induction therapy using optical coherence tomography angiography (OCT-A).

Setting:

Retrospective observational analysis

Methods:

Medical records of 10 eyes of 10 AMD patients (male/female 7/3, mean age 75.1 years old) who received initial three monthly intravitreal aflibercept induction therapy in our clinic from May to Aug 2016 were reviewed. OCT-A images were obtained before the induction therapy, at 1 week after the first injection, at 1 week before and after the second and the third injections of aflibercept. Then we evaluated the changes of the CNV size.

Results:

The mean CNV size was 0.629mm2 before aflibercept induction therapy and then decreased gradually to 0.520 mm2 (P=0.644) at 1 week after first injection, 0.439 mm2 (P=0.086) at 1 week before second injection, 0.347 mm2 (P=0.002) at 1 week after second injection, 0.340 mm2 (P=0.003) at 1 week before third injection and 0.320mm2 (P<0.001) at 1 week after third injection. The achievement rate of dry macula at 1 week after third injection was 90% (9/10 eyes).

Conclusions:

The CNV size decreased significantly compared to the baseline after the second intravitreal injection of aflibercept in treatment-naïve AMD patients.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy